Investigative Ophthalmology & Visual Science · 2018 · 133 citations · 52 references
MedicineNeuroscienceOphthalmologyCell TherapyNeurodegenerationRegenerative MedicineGlaucomaRetinal DegenerationRetinal Ganglion Cell FunctionRetinal Ganglion CellsBone Marrow - Derived CellsBone Marrow Stem Cell InfusionExtracellular VesiclesMesenchymal Stromal Cell Extracellular VesiclesRetinal Disease ModelsRetinal Ganglion Cell BiologyRetinal Ganglion Cell NeuroprotectionRetinal Neuroprotection
Purpose: To determine if bone marrow-derived stem cell (BMSC) small extracellular vesicles (sEV) promote retinal ganglion cell (RGC) neuroprotection in the genetic DBA/2J mouse model of glaucoma for 12 months. Methods: BMSC sEV and control fibroblast-derived sEV were intravitreally injected into 3-month-old DBA/2J mice once a month for 9 months. IOP and positive scotopic threshold responses were measured from 3 months: IOP was measured monthly and positive scotopic threshold responses were measured every 3 months. RGC neuroprotection was determined in wholemounts stained with RNA binding protein with multiple splicing (RBPMS), whereas axonal damage was assessed using paraphenylenediamine staining. Results: As expected, DBA/2J mice developed chronic ocular hypertension beginning at 6 months. The delivery of BMSC sEV, but not fibroblast sEV, provided significant neuroprotective effects for RBPMS+ RGC while significantly reducing the number of degenerating axons seen in the optic nerve. BMSC sEV significantly preserved RGC function in 6-month-old mice, but provided no benefit at 9 and 12 months. Conclusions: BMSC sEV are an effective neuroprotective treatment in a chronic model of ocular hypertension for 1 year, preserving RGC numbers and protecting against axonal degeneration.
52
The Ocular Hypertension Treatment Study
Mae O. Gordon · Archives of Ophthalmology · 2002 · 2.6K citations
Hongqi Xin, Yi Li, Yisheng Cui et al. · Journal of Cerebral Blood Flow & Metabolism · 2013 · 978 citations · Full text